|
**Overview**: Bad Obstetric History Panel**Introduction**: The Bad Obstetric History Panel is a diagnostic tool designed to screen for causes of bad obstetric history using serum samples. In India, recurrent pregnancy loss (RPL) affects 1-5 percent of couples, with bad obstetric history (BOH) including recurrent miscarriages, stillbirths, intrauterine death, or preterm delivery often linked to antiphospholipid syndrome (APS, 15-20 percent of RPL cases), thyroid disorders (subclinical hypothyroidism in 10-15 percent), infections (TORCH: toxoplasma, rubella, CMV), and thrombophilias. High burden in rural/low-SES women due to underdiagnosis, limited antenatal care, cultural stigma around infertility/miscarriage, delayed evaluation leading to repeated losses or infertility. Per obstetrics and immunology practices aligned with ICMR and FOGSI guidelines, the test employs immunoassay for comprehensive antibody/hormone/infection screening over 1-2 days with high sensitivity/specificity, valuable for identifying treatable causes and guiding low-dose aspirin, heparin, or levothyroxine. This diagnostic falls under pregnancy loss evaluation and targets women with BOH, addressing accurate detection to improve subsequent pregnancy outcomes. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing recurrent losses. Its serum-based approach ensures reliable performance in India's diverse laboratory settings.**Other Names**: BOH Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/endocrinology, compliant with 2025 standards.**Historical Milestone**: Expanded with APS and TORCH screening; in India, prominence with RPL clinics.**Purpose**: The test screens for 10 parameters including anti-cardiolipin IgG to guide BOH assessment, identify autoimmune/infectious/hormonal causes, inform preventive therapy.**Test Parameters**: 1. Anti-Cardiolipin IgG, 2. Anti-Cardiolipin IgM, 3. Lupus Anticoagulant, 4. Beta 2 Glycoprotein IgG, 5. Beta 2 Glycoprotein IgM, 6. TSH, 7. Free T4, 8. Toxoplasma IgM, 9. Rubella IgM, 10. CMV IgM.**Pretest Condition**: No fasting required; patients should report recurrent miscarriage, stillbirth, preterm delivery, or infertility history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on pregnancy losses, gestational age at loss, thrombotic events, family autoimmune history, infections.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated BOH causes including recurrent loss or thrombosis, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate treatable causes, necessitating specialist input. Normal may require further evaluation if history suggestive.**Specialist Consultation**: Obstetricians or reproductive endocrinologists should be consulted for management.**Additional Supporting Tests**: USG pelvis, karyotyping for confirmation.**Test Limitations**: May miss non-immune causes; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, RPL Studies India 2023. |
